Searchicon: search

Health Canada Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health

September 29, 2025

Kirkland, QC

Kirkland, QC, September 29, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced Health Canada’s approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable  suspension) – a new, once-yearly injectable product.


BRAVECTO® QUANTUM is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations with Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) for 12 months in dogs and puppies 6 months of age and older.      

It is also indicated for the treatment and control of tick infestations with Amblyomma americanum (lone star tick) for 8 months in dogs and puppies 6 months of age and older.


BRAVECTO® QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union in 2024, then the United States in July 2025, and now in Canada. In total, BRAVECTO® QUANTUM is currently approved in more than 50 countries worldwide.


“We’re proud to build on our leadership in long‑acting parasiticides with a new injection, administered by veterinarians, that provides uninterrupted flea and tick protection for up to 12 months.” said Susanne Martin, Companion Animal Business Unit Director, Merck Animal Health. “BRAVECTO® QUANTUM’s approval marks a meaningful advancement in Canadian pet care.’’


“Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be active year-round in some areas, especially knowing it only takes a few warm days for ticks to become active,” said Frank Guerino, Ph.D., associate vice president of Global Pharmaceutical Development, Merck Animal Health.

BRAVECTO® QUANTUM exemplifies Merck Animal Health’s commitment to science and has been recognized as a winner of the 2024 Edison Awards and the 2024 S&P Global Awards for Best New Companion Animal Product.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

Forward-Looking Statement of Merck &Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).